JP2009501724A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009501724A5 JP2009501724A5 JP2008521690A JP2008521690A JP2009501724A5 JP 2009501724 A5 JP2009501724 A5 JP 2009501724A5 JP 2008521690 A JP2008521690 A JP 2008521690A JP 2008521690 A JP2008521690 A JP 2008521690A JP 2009501724 A5 JP2009501724 A5 JP 2009501724A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- substituted
- alkynyl
- alkenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 72
- 125000000753 cycloalkyl group Chemical group 0.000 claims 56
- 125000000623 heterocyclic group Chemical group 0.000 claims 36
- 125000001072 heteroaryl group Chemical group 0.000 claims 33
- 150000001875 compounds Chemical class 0.000 claims 32
- 125000003342 alkenyl group Chemical group 0.000 claims 30
- 125000000304 alkynyl group Chemical group 0.000 claims 30
- 125000003118 aryl group Chemical group 0.000 claims 30
- 229910052736 halogen Inorganic materials 0.000 claims 30
- 150000002367 halogens Chemical class 0.000 claims 30
- 229910052760 oxygen Inorganic materials 0.000 claims 25
- 229910052717 sulfur Inorganic materials 0.000 claims 25
- 229910052799 carbon Inorganic materials 0.000 claims 21
- 125000004422 alkyl sulphonamide group Chemical group 0.000 claims 17
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 16
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 13
- 125000003545 alkoxy group Chemical group 0.000 claims 13
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 12
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 12
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims 12
- -1 alkyloxy sulfonamide Chemical class 0.000 claims 12
- 125000003710 aryl alkyl group Chemical group 0.000 claims 12
- 125000004421 aryl sulphonamide group Chemical group 0.000 claims 12
- 125000004104 aryloxy group Chemical group 0.000 claims 12
- 125000002837 carbocyclic group Chemical group 0.000 claims 12
- 125000004432 carbon atom Chemical group C* 0.000 claims 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims 12
- 125000001188 haloalkyl group Chemical group 0.000 claims 12
- 125000005842 heteroatom Chemical group 0.000 claims 12
- 125000001424 substituent group Chemical group 0.000 claims 12
- 229940124530 sulfonamide Drugs 0.000 claims 12
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims 10
- 125000005037 alkyl phenyl group Chemical group 0.000 claims 10
- 229910052757 nitrogen Inorganic materials 0.000 claims 10
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 6
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 150000003949 imides Chemical class 0.000 claims 6
- 125000001841 imino group Chemical group [H]N=* 0.000 claims 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 6
- 125000004430 oxygen atom Chemical group O* 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 239000012453 solvate Substances 0.000 claims 6
- 150000003456 sulfonamides Chemical class 0.000 claims 6
- 239000000651 prodrug Substances 0.000 claims 5
- 229940002612 prodrug Drugs 0.000 claims 5
- 102000014150 Interferons Human genes 0.000 claims 4
- 108010050904 Interferons Proteins 0.000 claims 4
- 229940079322 interferon Drugs 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 239000002777 nucleoside Substances 0.000 claims 3
- TZYVRXZQAWPIAB-FCLHUMLKSA-N 5-amino-3-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4h-[1,3]thiazolo[4,5-d]pyrimidine-2,7-dione Chemical compound O=C1SC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O TZYVRXZQAWPIAB-FCLHUMLKSA-N 0.000 claims 2
- 208000005176 Hepatitis C Diseases 0.000 claims 2
- 229950003954 isatoribine Drugs 0.000 claims 2
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 claims 2
- 102000006992 Interferon-alpha Human genes 0.000 claims 1
- 108010047761 Interferon-alpha Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 1
- 125000005422 alkyl sulfonamido group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000013160 medical therapy Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229960000329 ribavirin Drugs 0.000 claims 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 1
- 229940063673 spermidine Drugs 0.000 claims 1
- NHKZSTHOYNWEEZ-AFCXAGJDSA-N taribavirin Chemical compound N1=C(C(=N)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NHKZSTHOYNWEEZ-AFCXAGJDSA-N 0.000 claims 1
- 229950006081 taribavirin Drugs 0.000 claims 1
- 108090000195 villin Proteins 0.000 claims 1
- 0 *C(*=C)(C(N(CC(C1)OC2=II=IC3=C2I=II=I3)C1C(NC(C1)(C1*CCC=*1I(*S(N2*)(=O)=O)=C1)C2=O)=*)=O)N(*)I Chemical compound *C(*=C)(C(N(CC(C1)OC2=II=IC3=C2I=II=I3)C1C(NC(C1)(C1*CCC=*1I(*S(N2*)(=O)=O)=C1)C2=O)=*)=O)N(*)I 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69909605P | 2005-07-14 | 2005-07-14 | |
| US70055905P | 2005-07-18 | 2005-07-18 | |
| PCT/US2006/027605 WO2007009109A2 (en) | 2005-07-14 | 2006-07-14 | Antiviral compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009501724A JP2009501724A (ja) | 2009-01-22 |
| JP2009501724A5 true JP2009501724A5 (enExample) | 2009-07-09 |
Family
ID=37387254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008521690A Pending JP2009501724A (ja) | 2005-07-14 | 2006-07-14 | 抗ウイルス性化合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20070072809A1 (enExample) |
| EP (1) | EP1907403B1 (enExample) |
| JP (1) | JP2009501724A (enExample) |
| KR (1) | KR101345008B1 (enExample) |
| CN (1) | CN101243096B (enExample) |
| AR (1) | AR054838A1 (enExample) |
| AU (1) | AU2006267066A1 (enExample) |
| BR (1) | BRPI0613056A2 (enExample) |
| CA (1) | CA2614276A1 (enExample) |
| MX (1) | MX2008000609A (enExample) |
| NZ (1) | NZ564830A (enExample) |
| TW (1) | TWI389908B (enExample) |
| WO (1) | WO2007009109A2 (enExample) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003007697A (ja) * | 2001-06-21 | 2003-01-10 | Hitachi Kokusai Electric Inc | 半導体装置の製造方法、基板処理方法および基板処理装置 |
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| GEP20105124B (en) | 2005-07-25 | 2010-11-25 | Array Biopharma Inc | Novel macrocyclic inhibitors of hepatitis c virus replication |
| UA93990C2 (ru) | 2005-10-11 | 2011-03-25 | Интермюн, Инк. | Соединения и способ ингибирования репликации вируса гепатита c |
| KR20090024834A (ko) * | 2006-07-05 | 2009-03-09 | 인터뮨, 인크. | Ｃ형 간염 바이러스 복제의 신규 억제제 |
| US7935670B2 (en) | 2006-07-11 | 2011-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2374812B1 (en) | 2006-07-13 | 2015-04-15 | Achillion Pharmaceuticals, Inc. | 4-amino-4-oxobutanoyl Peptides as Inhibitors of Viral Replication |
| KR20090049600A (ko) * | 2006-09-13 | 2009-05-18 | 노파르티스 아게 | 마크로시클릭 ｈｃｖ 억제제 및 그의 용도 |
| US8343477B2 (en) | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
| US7772180B2 (en) | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7763584B2 (en) | 2006-11-16 | 2010-07-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7888464B2 (en) | 2006-11-16 | 2011-02-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8003604B2 (en) | 2006-11-16 | 2011-08-23 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| MX2009008872A (es) * | 2007-02-20 | 2009-10-30 | Novartis Ag | Compuestos macrociclicos como inhibidores de proteasa ns3 del virus de hepatitis c. |
| US20090155209A1 (en) * | 2007-05-03 | 2009-06-18 | Blatt Lawrence M | Novel macrocyclic inhibitors of hepatitis c virus replication |
| AP2009005057A0 (en) | 2007-05-10 | 2009-12-31 | Array Biopharma Inc | Novel peptide inhibitors of hepatitis c virus replication |
| JP5465667B2 (ja) | 2007-06-29 | 2014-04-09 | ギリアード サイエンシーズ， インコーポレイテッド | 抗ウイルス化合物 |
| BRPI0813500A2 (pt) | 2007-06-29 | 2015-01-06 | Gilead Sciences Inc | Compostos antivirais |
| TW200918524A (en) * | 2007-06-29 | 2009-05-01 | Gilead Sciences Inc | Antiviral compounds |
| US8383583B2 (en) | 2007-10-26 | 2013-02-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors |
| US8293705B2 (en) | 2007-12-21 | 2012-10-23 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
| CN104557861A (zh) | 2007-12-21 | 2015-04-29 | 阿维拉制药公司 | Hcv蛋白酶抑制剂和其用途 |
| US8309685B2 (en) | 2007-12-21 | 2012-11-13 | Celgene Avilomics Research, Inc. | HCV protease inhibitors and uses thereof |
| TWI487522B (zh) * | 2007-12-21 | 2015-06-11 | 賽基艾維洛米斯研究股份有限公司 | Ｈｃｖ蛋白酶抑制劑及其用途（一） |
| US8202996B2 (en) | 2007-12-21 | 2012-06-19 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
| EP2250174B1 (en) | 2008-02-04 | 2013-08-28 | IDENIX Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
| JP5490778B2 (ja) | 2008-03-20 | 2014-05-14 | エナンタ ファーマシューティカルズ インコーポレイテッド | Ｃ型肝炎ウイルス阻害剤としてのフッ素化大環状化合物 |
| KR20110005869A (ko) * | 2008-04-15 | 2011-01-19 | 인터뮨, 인크. | Ｃ형 간염 바이러스 복제의 신규한 마크로사이클릭 억제제 |
| US8163921B2 (en) | 2008-04-16 | 2012-04-24 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP5529120B2 (ja) | 2008-05-29 | 2014-06-25 | ブリストル−マイヤーズ スクイブ カンパニー | Ｃ型肝炎ウイルス阻害剤 |
| US7964560B2 (en) | 2008-05-29 | 2011-06-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8207341B2 (en) | 2008-09-04 | 2012-06-26 | Bristol-Myers Squibb Company | Process or synthesizing substituted isoquinolines |
| UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
| US8563505B2 (en) | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8044087B2 (en) | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP5723783B2 (ja) | 2008-12-10 | 2015-05-27 | アキリオン ファーマシューティカルズ，インコーポレーテッド | ウイルス複製の阻害剤としての新しい４−アミノ−４−オキソブタノイルペプチド |
| US8283310B2 (en) | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| UY32325A (es) * | 2008-12-19 | 2010-07-30 | Gilead Sciences Inc | Inhibidores de ns3 proteasa del vhc |
| US8102720B2 (en) * | 2009-02-02 | 2012-01-24 | Qualcomm Incorporated | System and method of pulse generation |
| AR075584A1 (es) * | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
| JP5690286B2 (ja) | 2009-03-04 | 2015-03-25 | イデニク プハルマセウティカルス，インコーポレイテッド | ホスホチオフェン及びホスホチアゾールｈｃｖポリメラーゼ阻害剤 |
| US8377962B2 (en) | 2009-04-08 | 2013-02-19 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
| US8232246B2 (en) | 2009-06-30 | 2012-07-31 | Abbott Laboratories | Anti-viral compounds |
| US9284307B2 (en) | 2009-08-05 | 2016-03-15 | Idenix Pharmaceuticals Llc | Macrocyclic serine protease inhibitors |
| CA2775697A1 (en) * | 2009-09-28 | 2011-03-31 | Intermune, Inc. | Cyclic peptide inhibitors of hepatitis c virus replication |
| US20110117055A1 (en) | 2009-11-19 | 2011-05-19 | Macdonald James E | Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds |
| US8476225B2 (en) | 2009-12-04 | 2013-07-02 | Gilead Sciences, Inc. | Antiviral compounds |
| CA2784748A1 (en) | 2009-12-18 | 2011-06-23 | Idenix Pharmaceuticals, Inc. | 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors |
| MX2013007677A (es) | 2010-12-30 | 2013-07-30 | Abbvie Inc | Inhibidores macrociclicos de serina proteasa de hepatitis. |
| EP2658858A4 (en) | 2010-12-30 | 2014-06-25 | Enanta Pharm Inc | MACROCYCLIC INHIBITORS OF HEPATITIS C SERINE PROTEASE PHENANTHRIDINE |
| US9353100B2 (en) | 2011-02-10 | 2016-05-31 | Idenix Pharmaceuticals Llc | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections |
| US20120252721A1 (en) | 2011-03-31 | 2012-10-04 | Idenix Pharmaceuticals, Inc. | Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor |
| US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| MX360452B (es) | 2012-10-19 | 2018-11-01 | Bristol Myers Squibb Co | Inhibidores del virus de la hepatitis c. |
| EP2914613B1 (en) | 2012-11-02 | 2017-11-22 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2914598B1 (en) | 2012-11-02 | 2017-10-18 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US9409943B2 (en) | 2012-11-05 | 2016-08-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP6342922B2 (ja) | 2013-03-07 | 2018-06-13 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｃ型肝炎ウイルス阻害剤 |
| US9115175B2 (en) | 2013-03-14 | 2015-08-25 | Achillion Pharmaceuticals, Inc. | Processes for Producing sovaprevir |
| WO2014145600A1 (en) | 2013-03-15 | 2014-09-18 | Achillion Pharmaceuticals, Inc. | Ach-0142684 sodium salt polymorphs, composition including the same, and method of manufacture thereof |
| WO2014145507A1 (en) | 2013-03-15 | 2014-09-18 | Achillion Pharmaceuticals, Inc. | A process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof |
| AU2014227849A1 (en) | 2013-03-15 | 2015-10-01 | Achillion Pharmaceuticals, Inc. | Sovaprevir polymorphs and methods of manufacture thereof |
| WO2015042375A1 (en) | 2013-09-20 | 2015-03-26 | Idenix Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
| WO2015134560A1 (en) | 2014-03-05 | 2015-09-11 | Idenix Pharmaceuticals, Inc. | Solid forms of a flaviviridae virus inhibitor compound and salts thereof |
| US20170135990A1 (en) | 2014-03-05 | 2017-05-18 | Idenix Pharmaceuticals Llc | Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection |
| SG11201705069YA (en) | 2014-12-26 | 2017-07-28 | Univ Emory | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
| EP3463469B1 (en) | 2016-05-27 | 2023-12-13 | Gilead Sciences, Inc. | Combination of ledipasvir and sofosbuvir for use in the treatment of hepatitis b virus infections in humans |
| PL3706762T3 (pl) | 2017-12-07 | 2025-02-10 | Emory University | N4-hydroksycytydyna i pochodne oraz związane z nimi zastosowania przeciwwirusowe |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816570A (en) * | 1982-11-30 | 1989-03-28 | The Board Of Regents Of The University Of Texas System | Biologically reversible phosphate and phosphonate protective groups |
| US4968788A (en) * | 1986-04-04 | 1990-11-06 | Board Of Regents, The University Of Texas System | Biologically reversible phosphate and phosphonate protective gruops |
| DE10399025I2 (de) * | 1990-09-14 | 2007-11-08 | Acad Of Science Czech Republic | Wirkstoffvorläufer von Phosphonaten |
| US6018049A (en) * | 1996-12-26 | 2000-01-25 | Shionogi & Co., Ltd. | Process for the preparation of carbamoylated imidazole derivatives |
| US6312662B1 (en) * | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
| US6457524B1 (en) * | 2000-09-15 | 2002-10-01 | Halliburton Energy Services, Inc. | Well cementing compositions and methods |
| HUP0500456A3 (en) * | 2000-11-20 | 2012-05-02 | Bristol Myers Squibb Co | Hepatitis c tripeptide inhibitors, pharmaceutical compositions comprising thereof and their use |
| EP1377568A1 (en) * | 2001-01-31 | 2004-01-07 | Warner-Lambert Company LLC | Method for carbamoylating alcohols |
| US6642204B2 (en) * | 2002-02-01 | 2003-11-04 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
| US7091184B2 (en) * | 2002-02-01 | 2006-08-15 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
| CA2369970A1 (en) * | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
| CA2370396A1 (en) * | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
| US6869964B2 (en) * | 2002-05-20 | 2005-03-22 | Bristol-Myers Squibb Company | Heterocyclicsulfonamide hepatitis C virus inhibitors |
| WO2004043339A2 (en) * | 2002-05-20 | 2004-05-27 | Bristol-Myers Squibb Company | Substituted cycloalkyl p1' hepatitis c virus inhibitors |
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| DE602004010137T2 (de) * | 2003-05-21 | 2008-09-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verbindungen als hepatitis c inhibitoren |
| US7132504B2 (en) * | 2003-11-12 | 2006-11-07 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7135462B2 (en) * | 2003-11-20 | 2006-11-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7309708B2 (en) * | 2003-11-20 | 2007-12-18 | Birstol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP1763531A4 (en) * | 2004-06-28 | 2009-07-01 | Boehringer Ingelheim Int | ANALOGUE OF HEPATITIS-C INHIBITING PEPTIDES |
| EP2316839B1 (en) * | 2004-07-16 | 2014-03-12 | Gilead Sciences, Inc. | Antiviral heterocyclic compounds having phosphonate groups |
-
2006
- 2006-07-13 TW TW095125697A patent/TWI389908B/zh not_active IP Right Cessation
- 2006-07-14 AU AU2006267066A patent/AU2006267066A1/en not_active Abandoned
- 2006-07-14 NZ NZ564830A patent/NZ564830A/en not_active IP Right Cessation
- 2006-07-14 CA CA002614276A patent/CA2614276A1/en not_active Abandoned
- 2006-07-14 BR BRPI0613056-9A patent/BRPI0613056A2/pt not_active IP Right Cessation
- 2006-07-14 EP EP06787506.2A patent/EP1907403B1/en not_active Not-in-force
- 2006-07-14 US US11/487,542 patent/US20070072809A1/en not_active Abandoned
- 2006-07-14 CN CN2006800298851A patent/CN101243096B/zh not_active Expired - Fee Related
- 2006-07-14 MX MX2008000609A patent/MX2008000609A/es active IP Right Grant
- 2006-07-14 KR KR1020087003628A patent/KR101345008B1/ko not_active Expired - Fee Related
- 2006-07-14 WO PCT/US2006/027605 patent/WO2007009109A2/en not_active Ceased
- 2006-07-14 JP JP2008521690A patent/JP2009501724A/ja active Pending
- 2006-07-14 AR ARP060103034A patent/AR054838A1/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009501724A5 (enExample) | ||
| JP2008510682A5 (enExample) | ||
| JP2012504126A5 (enExample) | ||
| CA2571984A1 (en) | Antiviral compounds | |
| CA2672652A1 (en) | Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | |
| RU2006134005A (ru) | Новые соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с | |
| JP2012528161A5 (enExample) | ||
| RU2014113539A (ru) | Тетрациклические гетероциклические соединения и способы их применения для лечения вирусных заболеваний | |
| JP2012512169A5 (enExample) | ||
| RU2008141682A (ru) | Лечение раковых заболеваний при помощи комбинации таксанов и 13-дезоксиантрациклинов | |
| JP2007525510A5 (enExample) | ||
| RU2009141187A (ru) | Серосодержащие соединения как ингибиторы ns3 серинпротеазы вируса гепатита с | |
| JP2012504132A5 (enExample) | ||
| JP2012504129A5 (enExample) | ||
| JP2011520906A5 (enExample) | ||
| CA2516016A1 (en) | Hepatitis c inhibiting compounds | |
| JP2005529069A5 (enExample) | ||
| RU2015123641A (ru) | 2-алкинилзамещенные производные нуклеозидов, предназначенные для лечения вирусных заболеваний | |
| JP2011511840A5 (enExample) | ||
| HRP20151075T1 (hr) | Kristalni (s)-izopropil 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-diokso-3,4-dihidropirimidin-1-(2h)-il)-4-fluoro-3-hidroksi-4-metiltetrahidrofuran-2-il)metoksi)(fenoksi)fosforil)amino) propanoat | |
| JP2013514359A5 (enExample) | ||
| RU2012132444A (ru) | Замещенные имидазопиридинил-аминопиридиновые соединения | |
| JP2008511633A5 (enExample) | ||
| HRP20120440T1 (hr) | Inhibitori virusa hepatitisa c | |
| RU2010123928A (ru) | Хиноксалинсодержащие соединения в качестве ингибиторов вируса гепатита с |